Madrigal's Cholesterol Drug Succeeds in Mid-Stage Trial Post author:Sam Post published:February 7, 2018 Post category:BioPharma MGL-3196 was well-tolerated with primarily mild and some moderate AEs. Source: BioSpace You Might Also Like Strongbridge Biopharma Announces New Employment Inducement Awards June 22, 2017 Amgen-Backed Immatics Lands $58 Million To Develop T-Cell Receptor Based Immunotherapies October 3, 2017 Bay Area's Nektar Inks $400 Million+ Autoimmune Disease Pact With Eli Lilly July 23, 2017
Amgen-Backed Immatics Lands $58 Million To Develop T-Cell Receptor Based Immunotherapies October 3, 2017
